Nature Research will give a webinar on June 12th at 23:00 GMT (Paris time: 17:00) with a presentation by Dr. Isaac Garcia-Murillas , the Naica crystal digital PCR system (Stilla Technologies, France) user from translational Senior Scientific Officer at the Institute of Cancer Research, in London.
Click on the link to register for registration:
http://www.workcast.com/register?cpak=2471184692681363&referrer=SPONSOR_STILLA_0618
Presenter introduction:
Dr. Isaac Garcia-Murillas is a translational senior scientific officer in the Molecular Oncology Research Group of Professor Nick Turner of the American Cancer Institute. He focuses on the clinical monitoring of therapeutic efficacy, the assessment of drug resistance, and the quantification of minimal residual lesions. Research on detection capabilities.
Abstract:
During the past years, interest in the use of circulating tumour DNA (ctDNA) as a non-invasive cancer biomarker has grown rapidly. Improvements in the genomic and molecular methods employed for ctDNA analysis are expanding the range of its potential applications, both in research settings and as a tool with clinical utility for cancer management. Several studies have demonstrated the attainability of ctDNA analysis to monitor response to treatment, assess the emergence of drug resistance and quantify minimal residual disease. In order to drive the implementation of ctDNA in personalized oncology and in cancer research several challenges remain to be circumvented.